[THE EFFICACY OF ENDOSCOPIC DUAL LASER TREATMENT FOR LOW GRADE UPPER TRACT UROTHELIAL CARCINOMA].


Journal

Harefuah
ISSN: 0017-7768
Titre abrégé: Harefuah
Pays: Israel
ID NLM: 0034351

Informations de publication

Date de publication:
Mar 2020
Historique:
entrez: 19 3 2020
pubmed: 19 3 2020
medline: 14 5 2020
Statut: ppublish

Résumé

Until recently, radical nephroureterectomy was considered the gold standard treatment for upper tract urothelial carcinoma (UTUC). Post-operative complications, long-term adverse effects of nephrectomy as well as the risk of contralateral recurrence have led to the development of nephron-sparing techniques. To evaluate the safety, complication rate, and oncologic outcomes of ureteroscopic nephron-sparing treatment for low-grade UTUC utilizing a hybrid laser system that incorporates two types of lasers: Nd:YAG and Ho:YAG. We reviewed the files of patients who underwent ureteroscopic treatment for UTUC with the hybrid laser system between the years 2014-2018. Only cases of low-grade UTUC and follow-up time of at least 6 months were included in the present study. The following were analyzed: demographic data, tumor histologic characteristics, peri-operative complications, histologic upgrade, oncologic outcomes (i.e: local recurrence, local spread, metastatic progression). A total of 38 patients, who underwent 74 ureteroscopies, met inclusion criteria. Mean tumor size was 16.2 mm. No intra-operative complications were recorded. Two post-operative complications were recorded in one patient - hematuria and retroperitoneal bleeding - both had been treated conservatively. Mean follow-up time was 21.8 months. Local recurrence rate was 73%. Histologic upgrade has been observed in two patients. Four patients (10.5%) were referred to radical nephroureterectomy. There were no cases of local spread, distant metastases or death during the follow-up period. Endoscopic dual-laser treatment for low-grade UTUC is safe, surgically feasible and associated with good short-term oncologic outcome. Patient selection and strict follow-up are mandatory.

Identifiants

pubmed: 32186786

Types de publication

Journal Article

Langues

heb

Sous-ensembles de citation

IM

Pagination

170-174

Auteurs

Asaf Shvero (A)

Department of Urology, Chaim Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Dorit E Zilberman (DE)

Department of Urology, Chaim Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Menahem Laufer (M)

Department of Urology, Chaim Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Zohar A Dotan (ZA)

Department of Urology, Chaim Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Jacob Ramon (J)

Department of Urology, Chaim Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Harry Z Winkler (HZ)

Department of Urology, Chaim Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Nir Kleinmann (N)

Department of Urology, Chaim Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH